188 related articles for article (PubMed ID: 7850923)
41. Intralesionally implanted cisplatin plus systemic carmustine for the treatment of brain tumor in rats.
Kong Q; Kleinschmidt-DeMasters BK; Lillehei KO
J Surg Oncol; 1998 Oct; 69(2):76-82. PubMed ID: 9808509
[TBL] [Abstract][Full Text] [Related]
42. Response of drug-sensitive and -resistant L1210 leukemias to high-dose chemotherapy.
Griswold DP; Trader MW; Frei E; Peters WP; Wolpert MK; Laster WR
Cancer Res; 1987 May; 47(9):2323-7. PubMed ID: 3567926
[TBL] [Abstract][Full Text] [Related]
43. Long-term persistence and cytokinetics of human tumor cells in vitro following high-dose alkylating agent exposure.
Holden SA; Teicher BA; Frei E
Cancer Lett; 1994 Dec; 87(2):211-22. PubMed ID: 7812943
[TBL] [Abstract][Full Text] [Related]
44. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.
Donnelly ET; Kelley M; Rockwell S
Cancer Chemother Pharmacol; 2004 Jan; 53(1):43-50. PubMed ID: 14574460
[TBL] [Abstract][Full Text] [Related]
45. cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice.
Schabel FM; Trader MW; Laster WR; Corbett TH; Griswold DP
Cancer Treat Rep; 1979; 63(9-10):1459-73. PubMed ID: 291480
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of chronic toxicity of cyclocreatine, a creatine analog, in Sprague Dawley rat after oral gavage administration for up to 26 weeks.
Kale VP; Wallery J; Novak J; Gibbs S; Bourdi M; Do MT; McKew JC; Terse PS
Regul Toxicol Pharmacol; 2020 Nov; 117():104750. PubMed ID: 32745584
[TBL] [Abstract][Full Text] [Related]
47. Nitrosourea combinations in lung cancer.
Livingston RB
Cancer Treat Rep; 1976 Jun; 60(6):757-760. PubMed ID: 182365
[TBL] [Abstract][Full Text] [Related]
48. Synergistic activity of recombinant human endostatin in combination with adriamycin: analysis of in vitro activity on endothelial cells and in vivo tumor progression in an orthotopic murine mammary carcinoma model.
Plum SM; Hanson AD; Volker KM; Vu HA; Sim BK; Fogler WE; Fortier AH
Clin Cancer Res; 2003 Oct; 9(12):4619-26. PubMed ID: 14555538
[TBL] [Abstract][Full Text] [Related]
49. Cyclocreatine (1-carboxymethyl-2-iminoimidazolidine) inhibits growth of a broad spectrum of cancer cells derived from solid tumors.
Lillie JW; O'Keefe M; Valinski H; Hamlin HA; Varban ML; Kaddurah-Daouk R
Cancer Res; 1993 Jul; 53(13):3172-8. PubMed ID: 8319226
[TBL] [Abstract][Full Text] [Related]
50. Endocrine and cytostatic treatment of experimental mammary cancer.
Fiebig HH; Schmähl D
Recent Results Cancer Res; 1980; 71():80-95. PubMed ID: 6768114
[No Abstract] [Full Text] [Related]
51. Minocycline in combination with chemotherapy or radiation therapy in vitro and in vivo.
Sotomayor EA; Teicher BA; Schwartz GN; Holden SA; Menon K; Herman TS; Frei E
Cancer Chemother Pharmacol; 1992; 30(5):377-84. PubMed ID: 1505076
[TBL] [Abstract][Full Text] [Related]
52. Phase II evaluation of the combination of triazinate, cyclophosphamide, doxorubicin, and cis-diamminedichloroplatinum(II) in patients with advanced adenocarcinoma of the lung.
Eagan RT; Frytak S; Ingle JN; Creagan ET; Nichols WC; Kvols LK
Cancer Treat Rep; 1980; 64(8-9):925-8. PubMed ID: 7192602
[TBL] [Abstract][Full Text] [Related]
53. Involvement of the mitochondrion respiratory chain in the synergy achieved by treatment of human ovarian carcinoma cell lines with both tumor necrosis factor-alpha and cis-diamminedichloroplatinum.
Uslu R; Bonavida B
Cancer; 1996 Feb; 77(4):725-32. PubMed ID: 8616765
[TBL] [Abstract][Full Text] [Related]
54. Creatine and cyclocreatine treatment of human colon adenocarcinoma xenografts: 31P and 1H magnetic resonance spectroscopic studies.
Kristensen CA; Askenasy N; Jain RK; Koretsky AP
Br J Cancer; 1999 Jan; 79(2):278-85. PubMed ID: 9888469
[TBL] [Abstract][Full Text] [Related]
55. Phase II study of cyclophosphamide, adriamycin, and cis-dichlorodiammineplatinum (II) by infusion in patients with adenocarcinoma and large cell carcinoma of the lung.
Eagan RT; Frytak S; Creagan ET; Ingle JN; Kvols LK; Coles DT
Cancer Treat Rep; 1979; 63(9-10):1589-91. PubMed ID: 227597
[No Abstract] [Full Text] [Related]
56. An adduct of cis-diamminedichloroplatinum(II) and poly(ethylene glycol)poly(L-lysine)-succinate: synthesis and cytotoxic properties.
Bogdanov AA; Martin C; Bogdanova AV; Brady TJ; Weissleder R
Bioconjug Chem; 1996; 7(1):144-9. PubMed ID: 8742003
[TBL] [Abstract][Full Text] [Related]
57. [Synergistic therapeutic effect of adriamycin with 5-fluor-uracil, with prednisolon and with cyclophosphamide on chemically induced mammary cancer of the rat (author's transl)].
Fiebig HH; Schmähl D
Klin Wochenschr; 1977 May; 55(9):445-50. PubMed ID: 406478
[No Abstract] [Full Text] [Related]
58. [Cis-dichlorodiammineplatinum, adriamycin and cyclophosphamide versus cis-dichlorodiammineplatinum, adriamycin, cyclophosphamide and CCNU in non-small cell carcinoma of the lung].
Sanz Ortiz J; Saiz García F
Med Clin (Barc); 1982 Nov 16-30; 79(9):403-6. PubMed ID: 6296560
[No Abstract] [Full Text] [Related]
59. Liposomal Delivery of Cyclocreatine Impairs Cancer Cell Bioenergetics Mediating Apoptosis.
Ganguly S; Elbayoumi T
Methods Mol Biol; 2021; 2275():173-186. PubMed ID: 34118038
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of chronic toxicity of cyclocreatine in beagle dogs after oral gavage administration for up to 23 weeks.
Wallery JJ; Kale VP; Novak J; Gibbs S; Do MT; McKew JC; Terse PS
Toxicol Appl Pharmacol; 2021 Nov; 430():115680. PubMed ID: 34411581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
